Wall Street analysts expect ZIOPHARM Oncology Inc (NASDAQ:ZIOP) to report earnings per share (EPS) of ($0.13) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for ZIOPHARM Oncology’s earnings, with estimates ranging from ($0.15) to ($0.12). ZIOPHARM Oncology posted earnings per share of ($0.11) in the same quarter last year, which indicates a negative year-over-year growth rate of 18.2%. The company is expected to issue its next earnings report on Thursday, February 15th.
On average, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.54) per share for the current financial year, with EPS estimates ranging from ($0.56) to ($0.52). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.64) to ($0.53). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.66 million. ZIOPHARM Oncology’s revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.11) EPS.
Several brokerages have weighed in on ZIOP. BidaskClub downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Friday. Finally, HC Wainwright reissued a “buy” rating and issued a $9.50 price target on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. ZIOPHARM Oncology has an average rating of “Hold” and a consensus price target of $12.58.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.51 on Tuesday. ZIOPHARM Oncology has a twelve month low of $4.03 and a twelve month high of $7.88.
COPYRIGHT VIOLATION NOTICE: “ZIOPHARM Oncology Inc (ZIOP) Expected to Announce Earnings of -$0.13 Per Share” was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.thestockobserver.com/2017/11/14/ziopharm-oncology-inc-ziop-expected-to-announce-earnings-of-0-13-per-share.html.
In other news, CEO Laurence James Neil Cooper bought 6,440 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average price of $4.68 per share, with a total value of $30,139.20. Following the completion of the acquisition, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 10.40% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in ZIOP. UBS Asset Management Americas Inc. lifted its holdings in shares of ZIOPHARM Oncology by 79.6% during the first quarter. UBS Asset Management Americas Inc. now owns 37,687 shares of the biotechnology company’s stock worth $239,000 after purchasing an additional 16,700 shares during the period. Parametric Portfolio Associates LLC lifted its holdings in ZIOPHARM Oncology by 325.7% in the first quarter. Parametric Portfolio Associates LLC now owns 81,011 shares of the biotechnology company’s stock valued at $514,000 after acquiring an additional 61,979 shares during the period. Teachers Advisors LLC lifted its holdings in ZIOPHARM Oncology by 8.3% in the first quarter. Teachers Advisors LLC now owns 214,906 shares of the biotechnology company’s stock valued at $1,363,000 after acquiring an additional 16,398 shares during the period. California Public Employees Retirement System lifted its holdings in ZIOPHARM Oncology by 95.9% in the first quarter. California Public Employees Retirement System now owns 435,532 shares of the biotechnology company’s stock valued at $2,541,000 after acquiring an additional 213,166 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in ZIOPHARM Oncology by 5.7% in the first quarter. Vanguard Group Inc. now owns 7,310,537 shares of the biotechnology company’s stock valued at $46,348,000 after acquiring an additional 396,678 shares during the period. 41.88% of the stock is owned by hedge funds and other institutional investors.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.